Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This entry represents a collection of pathogenic bacteria including Gram-positive Staphylococcus species and Gram-negative enteric pathogens like Shigella, enteropathogenic Escherichia coli (EPEC), and Salmonella. Staphylococcus spp. are major causes of skin, soft tissue, and systemic infections, often characterized by their ability to produce potent exotoxins and form biofilms (StatPearls, 2023). Shigella flexneri and Shigella sonnei are highly infectious agents of bacillary dysentery, primarily targeting the human colon through intracellular invasion (CDC, 2023). Enteropathogenic Escherichia coli (EPEC) is a leading cause of persistent diarrhea in infants, utilizing a type III secretion system to induce attaching and effacing lesions on the intestinal mucosa (NIH, 2013). Salmonella typhimurium and Salmonella enteritidis are key serovars responsible for non-typhoidal salmonellosis, typically manifesting as acute gastroenteritis following the ingestion of contaminated food (WHO, 2023). These pathogens are collectively targeted by various classes of antibiotics, though the emergence of multi-drug resistance remains a critical therapeutic challenge. Because this entry lists multiple distinct species and genera rather than a specific molecular target, it is classified as a pathogen group rather than a single therapeutic target.
Antibiotics targeting these pathogens typically act through the inhibition of cell wall synthesis (e.g., beta-lactams), protein synthesis (e.g., macrolides), or DNA replication and repair (e.g., fluoroquinolones).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pathogenic bacteria (Staphylococcus spp., Shigella spp., EPEC, Salmonella spp.).